BackgroundTrimetazidine (TMZ) is an anti-ischemic drug. In spite of its protective
effects on cardiovascular system, there is no scientific study on the
usefulness of TMZ treatment for prolonged QT interval and cardiac
hypertrophy induced by diabetes.ObjectivesTo evaluate the effects of TMZ on QT interval prolongation and cardiac
hypertrophy in the diabetic rats.MethodsTwenty-four male Sprague-Dawley rats (200-250 g) were randomly assigned into
three groups (n = 8) by simple random sampling method. Control (C), diabetic
(D), and diabetic administrated with TMZ at 10 mg/kg (T10). TMZ was
administrated for 8 weeks. The echocardiogram was recorded before isolating
the hearts and transfer to a Langendorff apparatus. Hemodynamic parameters,
QT and corrected QT interval (QTc) intervals, heart rate and antioxidant
enzymes were measured. The hypertrophy index was calculated. The results
were evaluated by one-way ANOVA and paired t-test using SPSS (version 16)
and p < 0.05 was regarded as significant.ResultsThe diabetic rats significantly indicated increased hypertrophy, QT and QTc
intervals and decreased Left ventricular systolic pressure (LVSP), Left
ventricular developed pressure (LVDP), rate pressure product (RPP), Max
dp/dt, and min dp/dt (±dp/dt max), heart rate, superoxide dismutase
(SOD), glutathione peroxidase (GPx) and catalase in the heart. Treatment
with TMZ in the diabetic animals was significantly improved these parameters
in comparison to the untreated diabetic group.ConclusionsTMZ improves QTc interval prolongation and cardiac hypertrophy in diabetes.
Background Gallic acid (GA) is a polyphenolic agent with interesting pharmacological impacts on the cardiovascular system. Objective The present study purposed to study the protective effects of GA at 25 and 50 mg/kg against isoproterenol (ISO)-induced cardiac damage in ischemia/reperfusion (I/R) in rats. Methods Male Wistar rats were randomly assigned into six groups: Control, Control treated with GA at 25 mg/kg (GA25), Control treated with GA at 50 mg/kg (GA50), Hypertrophic rats induced by ISO (ISO), Hypertrophic rats treated with GA at 25 mg/kg (ISO+GA25), and Hypertrophic rats treated with GA at 50 mg/kg (ISO+GA50). Heart isolation was performed to induce a cardiac I/R injury model. Cardiac hemodynamic parameters were recorded. Serum Lactate Dehydrogenase (LDH) and Creatine Kinase-MB (CK-MB) and cardiac Superoxide dismutases (SOD) levels were evaluated. The gene expression of Sarcoplasmic reticulum Ca2+-ATPase (SERCA2a) was assessed. Results We found that GA at 50 mg/kg was significantly increased cardiac function at post I/R period in ISO-induced hypertrophic hearts. Moreover, it suppressed cardiac hypertrophy, the serum LDH and CK-MB levels in ISO injected rats. Administration of GA at 50 mg/kg was significantly increased SOD level and SERCA2a gene expression in the hypertrophic hearts. Conclusion GA at 50 mg/kg could improve cardiac performance possibly by increasing antioxidant defense enzymes, reducing cell damage, and enhancing SERCA2a gene expression in hypertrophic heart induced by ISO in I/R injury conditions.
Aged heart is defined via structural and mitochondrial dysfunction of the heart. However, there is still no impressive compound to suppress and improve the abnormal alterations in cardiac function result from aging. Gallic acid (GA) is known to be an effective agent in improving cardiovascular disorders. In the present study, we exhibit the protective effects of GA against cardiac aging. Male Wistar rats were randomly divvied into four groups: Control, Control treated with GA at 25 mg/kg (GA25), aged rats induced by D-galactose (D-GAL), aged rats treated with GA at 25 mg/kg (D-GAL + GA25).Aging induced by D-GAL at 150 mL/kg via intraperitoneal injection for eight weeks. Aged rats treated with GA at 25 mg/kg (D-GAL GA25) by gavage for eight weeks. The blood samples were used to assessment biochemical factors and heart tissue was assessed for evaluating oxidative stress and the gene expression of molecular parameters. Histological examination of the heart was occurred. The D-GAL rats indicated cardiac hypertrophy, which was associated with reduced antioxidant activity of enzyme, increased oxidative marker and alterations in Sirtuin 1 (SIRT1), Peroxisome proliferator-activated receptor-gamma coactivator (PGC)-1alpha and Transcription Factor A, Mitochondrial (TFAM) genes expression in comparison to the control animals. Co-treatment with GA improved all these alterations. Taken together, GA could protect the heart against D-GAL-induced aging via antioxidant effects, and the enhancement of SIRT1, PGC-1α, and TFAM genes expression.
Trimetazidine (TMZ), as an anti-ischemic drug, plays a critical role in protecting against cardiovascular complications induced by diabetes. This study was therefore aimed to evaluate the protective effects of TMZ on reperfusion-induced arrhythmias in the diabetic rats. Male Sprague-Dawley rats (250±20 g) were randomly assigned to four (n=8): control rats (C), alloxan induced diabetic rats (D), diabetic rats treated with TMZ (10 mg/kg, D+T10), diabetic rats treated with TMZ (30 mg/kg, D+T30). TMZ was treated orally once daily for 8 weeks. Diabetes was induced by a single intraperitoneal injection of alloxan (120 mg/kg). Ischemia-reperfusion (I/R) was carried out via 30 min of ischemia and following120-min reperfusion. The magnitude and score of arrhythmia, the left ventricular function, infarct size, lactate dehydrogenase (LDH), myocardial creatine kinase (CK-MB) and troponin (cTnI) were measured. The findings were evaluated by two-way repeated measures and one-way ANOVA followed by LSD post hoc test and Fisher's exact test for incidence percentage. The duration, incidence and score of arrhythmia (p<0.001), infarct size (p<0.01) were significantly increased, the cardiac contractility (±dp/dt), LDH, CK-MB (p<0.001) and cTnI (p<0.05) were significantly decreased in the diabetic rats in comparison with the control group. However, treatment with TMZ in the diabetic rats was significantly improved the duration (p<0.001), incidence and score of arrhythmia,±dp/dt LDH, CK-MB, cTnI (p<0.05) and infarct size (p<0.01) in comparison with the untreated diabetic group. The present study indicates anti-arrhythmic effect of TMZ in reducing arrhythmias induced by reperfusion in the diabetic rats.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.